Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.

  2012influential reference
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Toll-like receptor modulators: a patent review (2006 – 2010)

  2011cited by this paper
• Leukocyte composition of human breast cancer

  2011cited by this paper
• Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.

  2011cited by this paper
• DNA methylation profiling reveals a predominant immune component in breast cancers

  2011cited by this paper
• In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

  2011cited by this paper
• Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).

  2011cited by this paper
• Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy

  2011influential reference
• RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.

  2011cited by this paper
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

  2011cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010influential reference
• Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

  2010cited by this paper
• Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

  2010cited by this paper
• Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

  2009cited by this paper
• Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

  2009cited by this paper
• Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

  2009cited by this paper
• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  2008cited by this paper
• Correlation between NK function and response to trastuzumab in metastatic breast cancer

  2007cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007influential reference
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

  2006cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• Malignant effusions and immunogenic tumour-derived exosomes.

  2002cited by this paper
• Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

  2001cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper

• Integrated Evaluation of Inflammatory, Nutritional, and Sarcopenia Markers to Predict Survival in Metastatic Breast Cancer Patients

  2023cites this paper
• Th2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC)

  2023cites this paper
• The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer

  2023cites this paper
• Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells

  2023cites this paper
• The effects of dexmedetomidine on postoperative tumor recurrence and patient survival after breast cancer surgery: a feasibility study

  2023cites this paper
• Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis

  2023cites this paper
• Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients.

  2023cites this paper
• Cancer: Immunology and Immunotharapy

  2022cites this paper
• Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.

  2022cites this paper
• Statistical Association Between Age Groups, Body Mass Index and Cancer Grade with Serological Concentrations of Immunological Biomarkers (Interleukin IL-1β, IL-6) among Females with Breast Cancer

  2022cites this paper
• Immunology and immunotherapy in breast cancer

  2022cites this paper
• Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity

  2022cites this paper
• The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer

  2022cites this paper
• Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation

  2022cites this paper
• Tumor-Infiltrating Lymphocytes in Low-Risk Patients With Breast Cancer Treated With Single-Dose Preoperative Partial Breast Irradiation

  2021cites this paper
• Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer

  2021cites this paper
• YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer.

  2021cites this paper
• Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice

  2021cites this paper
• Dissecting the biological heterogeneity of HER2-positive breast cancer

  2021cites this paper
• Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer

  2021cites this paper
• Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway

  2021influential citation
• Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer

  2021cites this paper
• Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS

  2021cites this paper
• Immuno-oncology in triple-negative breast cancer

  2021cites this paper
• Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy

  2021cites this paper
• GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy

  2021cites this paper
• The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

  2021cites this paper
• Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial–Mesenchymal Plasticity

  2021cites this paper
• Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated with Prognosis of HER2-Positive Breast Cancer Patients

  2021cites this paper
• Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications

  2021cites this paper
• Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer

  2021cites this paper
• Salvage therapy for prostate cancer after radical prostatectomy

  2021cites this paper
• Intermittent fasting in the prevention and treatment of cancer

  2021cites this paper
• CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses

  2020cites this paper
• Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

  2020cites this paper
• Tumor infiltrating lymphocytes in low-risk breast cancer patients treated with single dose pre-operative partial breast irradiation.

  2020cites this paper
• Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway

  2020cites this paper
• Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer

  2020cites this paper
• The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype

  2020influential citation
• Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

  2020cites this paper
• Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy

  2020cites this paper
• The Cancer-Immune Set Point in Oesophageal Cancer

  2020cites this paper
• Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

  2020cites this paper
• Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs)

  2020cites this paper
• A comprehensive analysis of IDO1 expression with tumour‐infiltrating immune cells and mutation burden in gynaecologic and breast cancers

  2020cites this paper
• Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis

  2020cites this paper
• Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer

  2019cites this paper
• Dynamic Targeting in Cancer Treatment

  2019cites this paper
• CMAR_A_194137 5971..5982

  2019cites this paper
• Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

  2019cites this paper
• MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure

  2019cites this paper
• Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer

  2019cites this paper
• CMAR_A_220327 10791..10800

  2019cites this paper
• Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas

  2019cites this paper
• Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node

  2019cites this paper
• Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population

  2019cites this paper
• Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy

  2019cites this paper
• Calcium signalling and breast cancer.

  2019cites this paper
• Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

  2019cites this paper
• Tumor infiltrating lymphocytes in early breast cancer.

  2018cites this paper
• Starvation, Stress Resistance, and Cancer.

  2018cites this paper
• Pushing the Limits of Cancer Therapy: The Nutrient Game

  2018cites this paper
• Significance of tumor‐infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer

  2018cites this paper
• New approaches in the neoadjuvant systemic therapy of breast cancer

  2018cites this paper
• Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer

  2018cites this paper
• Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

  2018cites this paper
• Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment

  2018cites this paper
• Monoclonal antibody‐based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER

  2018cites this paper
• A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer

  2018cites this paper
• The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages

  2018cites this paper
• Association of increased primary breast tumor AGR2 with decreased disease-specific survival

  2018cites this paper
• Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer

  2018cites this paper
• Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

  2018cites this paper
• The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages

  2018cites this paper
• Breast cancer intrinsic subtypes: a critical conception in bioinformatics

  2017cites this paper
• DNA methylation–based immune response signature improves patient diagnosis in multiple cancers

  2017cites this paper
• An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

  2017cites this paper
• Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

  2017cites this paper
• Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

  2017cites this paper
• Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials

  2017cites this paper
• Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

  2017cites this paper
• Breast cancer genomics and immuno-oncological markers to guide immune therapies.

  2017cites this paper
• Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

  2017cites this paper
• Tumor Immuno-Environment in Cancer Progression and Therapy.

  2017cites this paper
• Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.

  2017cites this paper
• Cancer as a Paradigm for Translational and Clinical Biomedical Research

  2017cites this paper
• Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

  2017cites this paper
• Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.

  2016cites this paper
• The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis

  2016cites this paper
• Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

  2016cites this paper
• Cancer Immunotherapy: A Review

  2016cites this paper
• New Strategies in Breast Cancer: Immunotherapy

  2016cites this paper
• Negative influence of programmed death‐1‐ligands on the survival of esophageal cancer patients treated with chemotherapy

  2016cites this paper
• Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

  2016cites this paper
• Conservation of immune gene signatures in solid tumors and prognostic implications

  2016cites this paper
• Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

  2016cites this paper
• PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women

  2016cites this paper
• Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.

  2016cites this paper
• The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3and their Impact on Recurrence in Breast Cancer Patients

  2016cites this paper
• Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein

  2016cites this paper